Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Ginkgo Bioworks Holdings, Inc. before investing.

In this article, we go over a few key elements for understanding Ginkgo Bioworks Holdings, Inc.’s stock price such as:

• Ginkgo Bioworks Holdings, Inc.’s current stock price and volume
• Why Ginkgo Bioworks Holdings, Inc.’s stock price changed recently
• Upgrades and downgrades for DNA from analysts
• DNA’s stock price momentum as measured by its relative strength

About Ginkgo Bioworks Holdings, Inc. (DNA)

Before we jump into Ginkgo Bioworks Holdings, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Want to learn more about Ginkgo Bioworks Holdings, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Ginkgo Bioworks Holdings, Inc..

Ginkgo Bioworks Holdings, Inc.’s Stock Price as of Market Close

As of April 07, 2026, 4:00 PM, CST, Ginkgo Bioworks Holdings, Inc.’s stock price was $6.820.

Ginkgo Bioworks Holdings, Inc. is down 0.73% from its previous closing price of $6.870.

During the last market session, Ginkgo Bioworks Holdings, Inc.’s stock traded between $6.320 and $6.860. Currently, there are approximately 57.08 million shares outstanding for Ginkgo Bioworks Holdings, Inc..

Ginkgo Bioworks Holdings, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Ginkgo Bioworks Holdings, Inc. Stock Price History

Ginkgo Bioworks Holdings, Inc.’s (DNA) price is currently up 11.26% so far this month.

During the month of April, Ginkgo Bioworks Holdings, Inc.’s stock price has reached a high of $7.110 and a low of $6.200.

Over the last year, Ginkgo Bioworks Holdings, Inc. has hit prices as high as $17.580 and as low as $5.370. Year to date, Ginkgo Bioworks Holdings, Inc.’s stock is down 17.93%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Ginkgo Bioworks Holdings, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 07, 2026, there were 0 analysts who downgraded Ginkgo Bioworks Holdings, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Ginkgo Bioworks Holdings, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Ginkgo Bioworks Holdings, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Ginkgo Bioworks Holdings, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Ginkgo Bioworks Holdings, Inc. (DNA) by visiting AAII Stock Evaluator.

Relative Price Strength of Ginkgo Bioworks Holdings, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 07, 2026, Ginkgo Bioworks Holdings, Inc. has a weighted four-quarter relative price strength of 0.41%, which translates to a Momentum Score of 52 and is considered to be Average.

Want to learn more about how Ginkgo Bioworks Holdings, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Ginkgo Bioworks Holdings, Inc. Stock Price: Bottom Line

As of April 7, 2026, Ginkgo Bioworks Holdings, Inc.’s stock price is $6.820, which is down 0.73% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Ginkgo Bioworks Holdings, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.